Referencias

1. Archer DF. Estradiol Gel: a new option in hormone replacement therapy. OBG Management. 2004:46-66.
2. Modena MG, et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005;52(1):1-10.
3. Archer. DF, et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause. 2012;19(6):622-9.
4. Panay N, et al. The 2013 British Menopause Society & Women’s Health Concern. Recommendations on hormone replacement therapy. Menopause Int. 2013;19(2):59-68.
5. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017; 24(7): 728-753.
6. Liu B, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;10:1-9.
7. Carranza-Liras S, et. al. Tiempo transcurrido a partir de la menopausia y su repercusión en el deterioro cognitivo. Ginel Obstet Mex. 2018; 86 (5): 289-96.
8. Travassos de Figueiredo Alves et al. Comparison of gel and patch estradiol replacement in Brazil, a tropical country. Maturitas. 2000;36(1):69-74.
9. Naunton M et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517-27.
10. Castelo-Branco et al. Clinical efficacy of estradiol transdermal system in the treatment of hot fashes in postmenopausal women. Res Rep Transderm Drug Deliv. 2014;3:1–8.
11. Bergendal A, et al. Riesgo de tromboembolia venosa asociada con el uso local y sistémico de terapia hormonal en mujeres peri y postmenopáusicas y en relación con el tipo y la vía de administración. Menopause. 2016;23(6):593-9.
12. Cannoletta M, et al. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health. 2014; 11 (6):745 – 57.
13. Ichikawa J, et al. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens. 2006; 19 (7):744 – 9.
14. Información para prescribir de Oestrogel®.
15. Vázquez Martínez JE, et al. Climaterio y menopausia. Guía de Práctica Clínica. COMEGO 2015. Pp: 147-78.
16. Canonico M, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006;4(6):1259-65.
17. Baber RJ, et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109-150.
18. Información para prescribir de Utrogestan®